Empirical use of growth hormone in IVF is useless: the largest randomized controlled trial.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The study focused on expected normal responders, limiting its applicability to other patient populations such as poor responders.

In addition, they provided funding for the statistical analysis.

Who Took Part

The abstract describes 288 patients taking part.

The age groups tagged for this paper are adults, women only.

This is a phase III open-label RCT involving 288 patients undergoing antagonist IVF cycles at the Ovo clinic in Montreal, Canada, between June 2014 and January 2020.

Patients were randomly assigned at a 1:1 ratio to either the GH or control group.

How the Study Was Run

In design terms this was a randomized and open-label study.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the patients and staff both knew the treatment.

Patients were expected normal responders.

The primary outcome was the clinical pregnancy rate, while secondary outcomes included the number of retrieved oocytes, good-quality embryos, maturation, fertilization, implantation, and miscarriage rates.

What Was Measured

The subject headings attached to it are Fertilization in Vitro, Pregnancy Rate, Ovulation Induction, Gonadotropin-Releasing Hormone, Embryo Transfer, Oocyte Retrieval and Human Growth Hormone.

Author keywords: in vitro fertilization, IVF, assisted reproductive technology, fertility agents, infertility and live birth.

What This Means in Plain Language

The paper is a randomized and open-label study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 288 patients.

The abstract goes on to report its results in about 13 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Human reproduction (Oxford, England)), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.